Literature DB >> 1847310

Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma.

A Neri1, F Barriga, G Inghirami, D M Knowles, J Neequaye, I T Magrath, R Dalla-Favera.   

Abstract

The Epstein-Barr virus (EBV) is associated with distinct forms of human lymphoid malignancies, including the endemic (eBL) and sporadic forms of Burkitt's lymphoma (sBL) and acquired immunodeficiency syndrome-associated non-Hodgkin lymphoma (AIDS-NHL). However, whether EBV has a pathogenetic role in these tumors or is a passenger virus has not been conclusively demonstrated. One element to distinguish between these two possibilities is to determine whether EBV infection has preceded and, thus, possibly contributed to clonal expansion, or whether infection has occurred after clonal expansion and thus is unlikely to contribute to pathogenesis. Toward this end we analyzed the structure of the heterogeneous genomic termini of EBV as markers of clonal infection in a panel of eBL (11 cases), sBL (9 cases), and AIDS-NHL (10 cases) biopsies. We show that EBV termini are uniformly clonal in sBL, eBL, and AIDS-NHL, strongly suggesting that EBV infection has preceded and, thus, most likely contributed to clonal expansion in these malignancies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847310

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis.

Authors:  I K Ruf; P W Rhyne; C Yang; J L Cleveland; J T Sample
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Epstein-Barr virus-positive inflammatory pseudotumor of the spleen with concomitant rectal cancer: a case report and review of the literature.

Authors:  Tomotaka Akatsu; Kaori Kameyama; Minoru Tanabe; Takashi Endo; Masaki Kitajima
Journal:  Dig Dis Sci       Date:  2007-04-04       Impact factor: 3.199

3.  Direct sequencing and characterization of a clinical isolate of Epstein-Barr virus from nasopharyngeal carcinoma tissue by using next-generation sequencing technology.

Authors:  Pan Liu; Xiaodong Fang; Zizhen Feng; Yun-Miao Guo; Rou-Jun Peng; Tengfei Liu; Zhiyong Huang; Yue Feng; Xiaoqing Sun; Zhiqiang Xiong; Xiaosen Guo; Sha-Sha Pang; Bo Wang; Xiaojuan Lv; Fu-Tuo Feng; Da-Jiang Li; Li-Zhen Chen; Qi-Sheng Feng; Wen-Lin Huang; Mu-Sheng Zeng; Jin-Xin Bei; Yong Zhang; Yi-Xin Zeng
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

Review 4.  Pathogenesis of AIDS-related lymphomas: molecular and histogenetic heterogeneity.

Authors:  G Gaidano; A Carbone; R Dalla-Favera
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

Review 5.  Epstein-Barr virus infection and human malignancies.

Authors:  G Niedobitek; N Meru; H J Delecluse
Journal:  Int J Exp Pathol       Date:  2001-06       Impact factor: 1.925

6.  Hairy cell leukemia and multiple autoimmune manifestations in a human immunodeficiency virus-infected patient.

Authors:  V R Arruda; J M Bizzacchi; I L Metze
Journal:  Ann Hematol       Date:  1993-06       Impact factor: 3.673

Review 7.  HIV-mediated B-lymphocyte activation and lymphomagenesis.

Authors:  J G Monroe; L E Silberstein
Journal:  J Clin Immunol       Date:  1995-03       Impact factor: 8.317

Review 8.  Epstein-Barr virus infection and associated diseases in children. I. Pathogenesis, epidemiology and clinical aspects.

Authors:  V Schuster; H W Kreth
Journal:  Eur J Pediatr       Date:  1992-10       Impact factor: 3.183

9.  Length of Epstein-Barr virus termini as a determinant of epithelial cell clonal emergence.

Authors:  Cary A Moody; Rona S Scott; Tao Su; John W Sixbey
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

Review 10.  Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity.

Authors:  G Gaidano; C Pastore; C Lanza; U Mazza; G Saglio
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.